Loading…
← CockpitCompetitor Analysis › UNICHEMLAB.NS Unichem Laboratories LimitedOpen in the cockpit ↗

Unichem Laboratories LimitedUNICHEMLAB.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum strong 62
Mkt cap
$361M
US dollars, full cap
Free float
28%
of shares outstanding
$/day
$305,044
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-11.7 pp
WACC 14.4%
Hurdle
n/a
no reverse DCF
Close · INR₹479.10
1D-0.5%
1W-5.7%
1M-5.0%
3M-9.5%
6M+28.3%
YTD+8.4%
1Y-0.1%
ATR %4.4%
Beta0.67
52w lowhigh30.3% off high

What Unichem Laboratories does

Employees: 2,815

Unichem Laboratories at a glance

Size Unichem Laboratories (UNICHEMLAB.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $361M, the 988th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹479.10 on 18 Nov 2026.

Performance Over six months the shares gained 28.3%, against -23.8% for the median peer and +3.8% for the India market (cap-weighted) — highest of 19 in its peer set.

Growth Revenue grew 6.4% over the last twelve months (peer median -6.5%); the operating margin is 4.8% (peer median -13.0%).

Valuation It trades at 1.6× enterprise value to sales against a peer median of 4.4× (4th cheapest of 18).

Capital Return on invested capital runs 11.7 points below its cost of capital (14.4% WACC).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026UNICHEMLAB.NS 128Peer median 77
Six months, rebased to 100: Unichem Laboratories against the median of its 20 peers (local-currency closes).

Unichem Laboratories financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹23.7B₹21.8B₹20.8B₹17.5B₹13.3B
Revenue growth—+5%+19%+32%—
Gross profit₹7.82B₹4.80B₹5.10B₹3.15B₹1.39B
EBITDA₹2.37B₹1.10B₹2.34B-₹765M-₹594M
Net income₹3.39B₹2.53B₹1.38B-₹938M-₹2.02B
Free cash flown/a-₹1.39B-₹1.62B-₹302M-₹1.45B
Capital expendituren/a₹1.23B₹1.37B₹226M₹443M
Total debt₹4.98B₹5.00B₹4.60B₹2.48B₹3.14B

Quarterly statements and history in the cockpit →

Unichem Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-75%-50%-25%0%+25%-20%0%45693010890056900001534886301111MPLT002872SPRYPBYI688399IRD455200286830053442CUNICHEMLAB.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Unichem Laboratories is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×25×50×75×4569301089005690000153PBYIIRD002868SHUKRAPHAR42CUNICHEMLAB.NSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Unichem Laboratories is the large dot.

Unichem Laboratories competitors and peer comparison

How Unichem Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Unichem Laboratories against its 20 peers (data as of 18 Nov 2026)
MeasureUNICHEMLAB.NSPeer medianRank in peer set
1-month return-5.0%-13.3%6th highest of 20
6-month return+28.3%-23.8%highest of 19
Distance from 52-week high-30.3%-41.3%7th highest of 21
Revenue growth (TTM)+6.4%-6.5%7th highest of 18
Operating margin4.8%-13.0%5th highest of 18
EV / Sales1.6×4.4×4th cheapest of 18
ROIC minus cost of capital-11.7 pp-6.6 pp3rd lowest of 16
EV / EBITDA15.7×8.7×3rd most expensive of 6
Net debt / EBITDA1.4×-0.0×most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Unichem Laboratories UNICHEMLAB.NSIndia$361M+28%+6%5%1.6×n/an/a
KYORIN Pharmaceutical 4569.TJapan$360M-22%-6%2%0.5×6.7%+4.2%
Tuoxin Pharmaceutical 301089.SZChina$363M-28%+17%-20%5.3×n/an/a
Pharmicell 005690.KSSouth Korea$364M-55%+46%32%3.0×-7.9%+24.8%
Anhui Fengyuan Pharmaceutical 000153.SZChina$355M-17%-24%3%1.1×3.6%+3.1%
ASKA Pharmaceutical 4886.TJapan$354M-24%+11%n/an/an/an/a
Guangdong Lifestrong Pharmacy 301111.SZChina$368M-33%+7%-2%7.2×n/an/a
6467 6467.TWTaiwan$368Mn/an/a-2,618%1,407.9×n/an/a
MapLight Therapeutics MPLTUnited States$370M-76%n/an/an/an/an/a
Tiansheng Pharmaceutical 002872.SZChina$371M-1%-1%-13%4.9×22.2%-15.7%
ARS Pharmaceuticals SPRYUnited States$371M-53%-14%-162%2.9×n/an/a
Guizhou Yibai Pharmaceutical 600594.SSChina$351M-23%-26%-15%1.9×8.0%-11.3%
Puma Biotechnology PBYIUnited States$373M+3%+9%11%1.2×0.1%+0.3%
Jiangsu Bioperfectus Technologies 688399.SSChina$374M-51%-8%-23%4.4×n/an/a
Opus Genetics IRDUnited States$379M-22%-46%-778%41.2×n/an/a
JCR Pharmaceuticals 4552.TJapan$379M-5%+3%-14%2.9×n/an/a
Lifecome Biochemistry 002868.SZChina$384M-54%-23%-3%6.2×n/an/a
SanBio 4592.TJapan$386M-55%n/an/an/an/an/a
Gansu Longshenrongfa Pharmaceutical Industry 300534.SZChina$386M-2%-21%8%3.7×20.9%+28.2%
Shukra Pharmaceuticals SHUKRAPHAR.NSIndia$387Mn/a+222%54%32.0×n/an/a
iX Biopharma 42C.SISingapore$387M+28%-12%-140%71.6×n/an/a

Questions

Which companies are Unichem Laboratories's closest peers?
The cockpit's peer set: KYORIN Pharmaceutical (4569.T), Tuoxin Pharmaceutical (301089.SZ), Pharmicell (005690.KS), Anhui Fengyuan Pharmaceutical (000153.SZ), ASKA Pharmaceutical (4886.T), Guangdong Lifestrong Pharmacy (301111.SZ), 6467 (6467.TW), MapLight Therapeutics (MPLT).
Is Unichem Laboratories expensive compared with its peers?
On ev / sales it trades at 1.6× against a peer median of 4.4×, 4th cheapest of 18 in its peer set.
How has Unichem Laboratories stock performed?
Over six months to 18 Nov 2026 the shares returned +28.3% against -23.8% for the median peer; over one year -0.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.